Journal
OBESITY
Volume 19, Issue 1, Pages 17-22Publisher
WILEY
DOI: 10.1038/oby.2010.116
Keywords
-
Categories
Funding
- AHA
- National Sleep Foundation
- American Sleep Medicine Foundation
- Philips
- Sepracor
- NMT
- Apnex
- Itamar
- Pfizer
- SGS
- Medtronic
- Ethicon
- Cephalon
- SHC
- [K24 HL 093218]
- [R01 HL090897-01]
- [R01 HL085188-01]
- [R01 HL73146]
- [R01-HL075678]
- [R01 DK076937]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073146, R01HL085188, K24HL093218, R01HL090897, R01HL075678] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076937] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Despite the high prevalence of obstructive sleep apnea (OSA) in type 2 diabetes mellitus (DM), the attributable vascular risk from each condition is unknown. We hypothesize that OSA may have a similar effect on vascular function as type 2 diabetes does. Healthy normal-weight subjects, healthy obese subjects, subjects with type 2 diabetes, and obese subjects with OSA were enrolled. Vascular function was assessed with brachial artery ultrasound for flow-mediated dilatation (FMD) and in skin microcirculation by laser Doppler flowmetry. One hundred fifty-three subjects were studied: healthy normal-weight controls (NCs) (n = 14), healthy obese controls (OCs) (n = 33), subjects with DM (n = 68), and obese subjects with OSA (n = 38). The DM group did not undergo sleep study and thus may have had subclinical OSA. The OSA and type 2 diabetes groups had impaired FMD as compared to both the normal-weight and OC groups (5.8 +/- 3.8%, 5.4 +/- 1.6% vs. 9.1 +/- 2.5%, 8.3 +/- 5.1%, respectively, P < 0.001, post hoc Fischer test). When referenced to the NC group, a multiple linear regression model adjusting for covariates found that baseline brachial artery diameter (beta = -3.75, P < 0.001), OSA (beta = -2.45, P = 0.02) and type 2 diabetes status (beta = -2.31, P = 0.02), negatively predicted % FMD. OSA status did not seem to affect nitroglycerin-induced vasodilation (endothelium-independent) of the brachial artery or vascular function in the skin microcirculation. OSA impairs endothelial function in the brachial artery to a similar degree as type 2 diabetes does. OSA, however, does not appear to affect brachial endothelium-independent vasodilation or skin microcirculatory function. Treatment of OSA in patients with concomitant type 2 diabetes, therefore, may be a potential therapeutic option to improve macro-, but not microvascular outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available